MNKD

Mannkind Corp

3.50

Oct 30 • 3:59 PM ET 0.00 (0.00%)

3.50

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: INSM LQDA XERS SVRA UTHR AVLN TNDM AQST NVO LLY

| Held by: VTI IWM XBI VXF IWO IBB VTWO FYC SCHA VHT

Scroll to Statements

Index	RUT
Market Cap	1.13B
Enterprise Value	1.45B
Income	-43.61M
Sales	393.63M
Book/sh	-0.22
Cash/sh	0.35
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	592
IPO	Jul 28, 2004

P/E	-
Forward P/E	1051.05
PEG	25.17
P/S	2.86
P/B	-
P/C	10.13
P/FCF	-
EV/EBITDA	41.64
EV/Sales	3.69
Quick Ratio	1.41
Current Ratio	1.72
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.14
EPS next Y	0.00
EPS next Q	-0.06
EPS this Y	-1050.00%
EPS next Y	101.75%
EPS next 5Y	41.75%
EPS past 3/5Y	- -
Sales past 3/5Y	51.80% 39.89%
EPS Y/Y TTM	-223.84%
Sales Y/Y TTM	30.46%
EPS Q/Q	-3033.33%
Sales Q/Q	42.92%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-700.00% 1.20%

Insider Own	4.53%
Insider Trans	-1.41%
Inst Own	54.69%
Inst Trans	-3.86%
ROA	-7.62%
ROE	-
ROIC	-12.25%
Gross Margin	72.16%
Oper. Margin	3.37%
Profit Margin	-11.08%
SMA20	6.54%
SMA50	-2.32%
SMA200	-6.16%
Trades

Shs Outstand	309.91M
Shs Float	306.97M
Short Float	8.30%
Short Ratio	6.01
Short Interest	25.48M
52W High	6.51 -46.24%
52W Low	2.23 56.95%
Volatility	4.30% 5.65%
ATR (14)	0.18
RSI (14)	55.60
Beta	1.08
Rel Volume	0.47
Avg Volume	4.24M
Volume	2,009,181

Perf Week	9.72%
Perf Month	-11.39%
Perf Quarter	-7.89%
Perf Half Y	23.24%
Perf YTD	-38.27%
Perf Year	-36.94%
Perf 3Y	-15.87%
Perf 5Y	-25.69%
Perf 10Y	55.38%
Recom	1.22
Target Price	8.08
Prev Close	3.50
Price	3.50
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$8.08

Implied Upside

+130.9%

Analysts13incl. previous ratings

Rating Distribution12 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 19, 2026	Initiated	CChardan Capital Markets	Buy	$10	+185.7%
Feb 27, 2026	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$3.50	0.0%
Nov 24, 2025	Initiated	TTruist	Buy
Nov 13, 2025	Initiated	LLeerink Partners	Outperform	$7	+100.0%
Oct 20, 2025	Initiated	WWells Fargo	Overweight	$10	+185.7%
Oct 10, 2025	Initiated	LLeerink Partners	Outperform	$9	+157.1%
Jul 16, 2025	Resumed	HH.C. Wainwright	Buy	$9	+157.1%
Apr 10, 2025	Initiated	MMizuho	Outperform	$12	+242.9%
Feb 10, 2025	Initiated	WWedbush	Outperform	$11	+214.3%
Dec 20, 2024	Initiated	WWells Fargo	Overweight	$9	+157.1%
Dec 19, 2024	Upgrade	RRBC Capital Mkts	Sector Perform → Outperform	$7 → $10	+185.7%
Sep 09, 2024	Resumed	LLeerink Partners	Outperform	$7 → $8	+128.6%
Jun 13, 2024	Initiated	RRodman & Renshaw	Buy	$8	+128.6%
Oct 10, 2023	Initiated	WWedbush	Outperform	$10	+185.7%
May 14, 2021	Initiated	RRBC Capital Mkts	Sector Perform	$5	+42.9%
Dec 24, 2019	Initiated	OOppenheimer	Outperform	$2.50	-28.6%
Oct 25, 2019	Initiated	CCantor Fitzgerald	Overweight	$3	-14.3%
May 14, 2019	Initiated	BBTIG Research	Buy	$3	-14.3%
Mar 04, 2019	Initiated	SSVB Leerink	Outperform	$3	-14.3%
Feb 22, 2019	Initiated	SSVB Leerink	Outperform	$3	-14.3%

Today 09:42AM	MannKind's Furosix Ramp And Pediatric Afrezza Uptake Face First Real Test After Catalyst Sweep (Earnings Whispers)
Oct-29-26 04:01PM	MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 (GlobeNewswire)
Oct-14-26 04:01PM	MannKind to Participate in the Chardan Healthcare Conference (GlobeNewswire) +5.63%
Oct-09-26 08:00PM	MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) (GlobeNewswire)
Sep-09-26 08:36AM	MannKind Expands Into Weight Loss With Rose Pharma Deal Heres What Investors Are Watching (Stocktwits) -5.29%
06:30AM	Loading…
06:30AM	MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management (GlobeNewswire)
Sep-02-26 08:30AM	MannKind to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-06-26 01:11AM	MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts ... (GuruFocus.com) -5.12%
Aug-05-26 04:44PM	MannKind: Q2 Earnings Snapshot (Associated Press)
04:01PM	MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-26 06:30AM	MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF (GlobeNewswire)
Jul-28-26 04:01PM	MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026 (GlobeNewswire)
Jul-24-26 01:20PM	MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost (Stocktwits) +6.17%
08:56AM	MannKind shares surge after FDA approves Furoscix ReadyFlow and company secures $50 million financing (InvestorsHub)
06:35AM	MannKind Announces $50 Million Private Placement (GlobeNewswire)
06:30AM	Loading…
06:30AM	MannKind Announces FDA Approval of Furoscix ReadyFlow, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease (GlobeNewswire)
06:21AM	MNKD Stock Rises Premarket As FDA Verdict Nears Retail Optimism Builds (Stocktwits)
Jun-23-26 09:00AM	MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D (GlobeNewswire)
Jun-05-26 07:35PM	Data at ADA 2026 Highlights Key Findings from Clinical and Real-World Studies of MannKind's Afrezza (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems (GlobeNewswire)
Jun-03-26 06:05AM	MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF (GlobeNewswire)
May-29-26 03:43PM	MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children (Stocktwits)
02:00PM	MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval (GlobeNewswire)
12:30PM	MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes (GlobeNewswire)
May-28-26 07:19AM	MNKD Stock Eyes Best Month Since 2022 Ahead Of FDA Decision On Pediatric Diabetes Treatment (Stocktwits)
May-27-26 04:00PM	MannKind to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
09:05AM	MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems (GlobeNewswire)
May-12-26 10:30AM	The $59B Quiet Shift Reshaping How Patients Access Care (PR Newswire)
May-06-26 04:36PM	MannKind: Q1 Earnings Snapshot (Associated Press) +24.48%
04:01PM	MannKind Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
10:30AM	BC-Most Active Stocks (Associated Press)
06:30AM	Loading…
06:30AM	MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases (GlobeNewswire)
Apr-29-26 04:01PM	MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 (GlobeNewswire)
Mar-18-26 10:00AM	A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. (PR Newswire)
Mar-09-26 09:05AM	MannKind to Present New Data From Pediatric and Adult Studies of Afrezza at ATTD 2026 (GlobeNewswire)
Mar-05-26 08:02PM	MannKind Corp (MNKD) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com) -7.77%
04:30PM	MannKind Announces Settlement of Convertible Senior Notes (GlobeNewswire)
Mar-04-26 09:00AM	MannKind to Participate in Upcoming Investor Conferences (GlobeNewswire)
05:37AM	MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets (Insider Monkey)
Feb-28-26 09:05PM	MannKind at Oppenheimer: 2025 Revenue Jumps 46%, Eyes $450M+ in 2026 on Afrezza and FUROSCIX (MarketBeat)
01:25PM	MannKind Corporation (MNKD): A Bull Case Theory (Insider Monkey)
Feb-27-26 12:30PM	What's Going On With MannKind Stock Friday? (Benzinga)
Feb-26-26 05:03PM	MannKind Q4 Earnings Call Highlights (MarketBeat) -7.43%
12:30PM	Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics (Zacks)
12:15PM	MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:17AM	MannKind: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-19-26 09:00AM	MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-18-26 09:00AM	MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-13-26 12:01AM	Top Picks 2026- MannKind Corp. MNKD (MoneyShow)
Feb-09-26 06:05AM	MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) (GlobeNewswire)
Jan-29-26 01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire)
Jan-26-26 10:16AM	Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets (PR Newswire)
06:05AM	MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy (GlobeNewswire)
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
Jan-21-26 10:06AM	Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer (Zacks)
08:36AM	MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
Jan-19-26 12:53PM	Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease (Zacks)
08:02AM	MannKind Corporation (MNKD) Reveals 2026 Growth Drivers (Insider Monkey)
Jan-16-26 11:15AM	Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia (Zacks) -6.63%
Jan-15-26 10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
Jan-14-26 10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
Jan-13-26 12:00PM	MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
10:39AM	6 stocks and ETFs that these unsung market heroes see outperforming in 2026 (MarketWatch)
Jan-12-26 03:57PM	6 stocks and ETFs that these unsung market heroes see outperforming in 2026 (MarketWatch)
Jan-08-26 08:05AM	MannKind Provides Business Updates and 2026 Growth Drivers (GlobeNewswire)
Jan-01-26 06:29AM	MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care (Insider Monkey)
Dec-23-25 08:05AM	MannKind Shares FUROSCIX Business Updates (GlobeNewswire)
Dec-01-25 08:05AM	MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease (GlobeNewswire)
Nov-11-25 04:05PM	MannKind to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
Nov-10-25 08:00AM	MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease (GlobeNewswire)
Nov-08-25 12:00PM	MannKind Corp (MNKD) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansions ... (GuruFocus.com)
Nov-06-25 09:00AM	MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes (GlobeNewswire) -5.94%
Nov-05-25 09:30AM	MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) +10.58%
09:15AM	MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates (Zacks)
08:08AM	MannKind: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 07:56AM	MannKind Corp (MNKD) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Oct-30-25 10:00AM	Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-29-25 04:05PM	MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025 (GlobeNewswire)
Oct-13-25 08:05AM	MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes (GlobeNewswire)
Oct-07-25 09:00AM	MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care (GlobeNewswire)
Sep-29-25 06:05AM	MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer (GlobeNewswire)
Sep-10-25 11:30AM	Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? (Zacks)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +25.05%
Aug-31-25 12:16AM	H.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD) (Insider Monkey)
Aug-29-25 09:38AM	Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
05:10AM	MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza (Insider Monkey)
Aug-27-25 04:05PM	MannKind to Present at Upcoming Investor Conferences (GlobeNewswire) +11.06%
08:05AM	MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy (GlobeNewswire)
04:46AM	New Strong Sell Stocks for August 27th (Zacks)
Aug-25-25 11:56PM	Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7 (Insider Monkey) -5.11%
07:30AM	MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases (GlobeNewswire)
Aug-22-25 11:45PM	Leerink Partners Reiterates a Buy on MannKind Corporation (MNKD), Keeps the PT (Insider Monkey)
Aug-17-25 06:26PM	MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline (Insider Monkey)
Aug-06-25 09:30AM	MannKind (MNKD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -13.16%
08:25AM	MannKind (MNKD) Reports Break-Even Earnings for Q2 (Zacks)
07:10AM	MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement (GlobeNewswire)
07:05AM	MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update (GlobeNewswire)
Aug-05-25 09:56AM	MannKind Corp (MNKD) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-04-25 10:01AM	Wedbush Maintains a Buy on MannKind Corporation (MNKD) (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Binder Steven B.	Director	Sep 25 '26	Sale	3.29	39,051	128,478	713,258	Sep 28 08:26 PM
STEVEN BINDER	Director	Sep 25 '26	Proposed Sale	3.29	39,051	128,478		Sep 25 04:17 PM
Binder Steven B.	Director	Sep 10 '26	Sale	3.81	33,558	127,856	752,309	Sep 14 08:00 PM
STEVEN BINDER	Director	Sep 10 '26	Proposed Sale	3.94	33,558	132,219		Sep 10 04:43 PM
Binder Steven B.	Director	Aug 07 '26	Sale	4.06	39,051	158,547	785,867	Aug 10 08:44 PM
STEVEN BINDER	Director	Aug 07 '26	Proposed Sale	3.89	39,051	151,908		Aug 07 04:39 PM
Tross Stuart A	Chief People & Workpl Officer	Jul 15 '26	Option Exercise	0.00	93,790	0	1,123,950	Jul 17 09:45 PM
Castagna Michael	Chief Executive Officer	Jul 15 '26	Option Exercise	0.00	350,260	0	2,796,979	Jul 17 09:44 PM
Singh Sanjay R	EVP Technical Operations	Jul 15 '26	Option Exercise	0.00	70,550	0	525,761	Jul 17 09:44 PM
Thomson David	EVP Genl Counsel & Secretary	Jul 15 '26	Option Exercise	0.00	93,790	0	920,089	Jul 17 09:43 PM
Thomson David	EVP Genl Counsel & Secretary	Jul 17 '26	Sale	4.05	24,109	97,641	797,554	Jul 17 09:43 PM
Binder Steven B.	Director	Jul 15 '26	Option Exercise	0.00	93,790	0	901,798	Jul 17 09:42 PM
Binder Steven B.	Director	Jul 17 '26	Sale	4.06	52,485	213,089	824,918	Jul 17 09:42 PM
DAVID THOMSON	Officer	Jul 17 '26	Proposed Sale	4.04	24,109	97,400		Jul 17 04:21 PM
STEVEN BINDER	Director	Jul 17 '26	Proposed Sale	4.04	52,485	212,039		Jul 17 04:21 PM
Binder Steven B.	Director	May 12 '26	Sale	3.29	16,940	55,733	808,008	May 13 08:30 PM
Thomson David	EVP Genl Counsel & Secretary	May 12 '26	Sale	3.29	3,033	9,979	826,299	May 13 08:30 PM
DAVID THOMSON	Officer	May 12 '26	Proposed Sale	3.36	10,113	33,980		May 12 04:34 PM
STEVEN BINDER	Director	May 12 '26	Proposed Sale	3.36	16,940	56,918		May 12 04:34 PM
Castagna Michael	Chief Executive Officer	Mar 10 '26	Buy	2.59	100,000	259,000	2,575,911	Mar 10 09:30 PM
Tross Stuart A	Chief People & Workpl Officer	Jan 08 '26	Sale	6.33	47,006	297,548	985,007	Jan 09 08:30 PM
STUART A TROSS	Officer	Jan 08 '26	Proposed Sale	6.33	47,000	297,510		Jan 08 04:07 PM
Castagna Michael	Chief Executive Officer	Dec 17 '25	Option Exercise	4.55	65,804	299,408	2,570,596	Dec 19 08:00 PM
Castagna Michael	Chief Executive Officer	Dec 17 '25	Sale	6.01	65,804	395,482	2,504,792	Dec 19 08:00 PM
Castagna Michael	Chief Executive Officer	Dec 16 '25	Option Exercise	4.55	21,310	96,960	2,526,102	Dec 16 08:15 PM
Castagna Michael	Chief Executive Officer	Dec 12 '25	Option Exercise	4.55	20,806	94,667	2,525,598	Dec 16 08:15 PM
Castagna Michael	Chief Executive Officer	Dec 16 '25	Sale	6.00	21,310	127,860	2,504,792	Dec 16 08:15 PM
Castagna Michael	Chief Executive Officer	Dec 12 '25	Sale	6.00	20,806	124,836	2,504,792	Dec 16 08:15 PM
MICHAEL CASTAGNA	Director	Dec 12 '25	Proposed Sale	5.81	107,920	627,015		Dec 12 04:26 PM
Castagna Michael	Chief Executive Officer	Dec 02 '25	Option Exercise	4.55	107,920	491,036	2,612,712	Dec 04 07:32 PM
Castagna Michael	Chief Executive Officer	Dec 02 '25	Sale	5.57	107,920	601,114	2,504,792	Dec 04 07:32 PM
Thomson David	EVP Genl Counsel & Secretary	Dec 02 '25	Option Exercise	4.58	147,780	676,788	989,499	Dec 04 07:27 PM
Thomson David	EVP Genl Counsel & Secretary	Dec 02 '25	Sale	5.57	147,780	823,135	841,719	Dec 04 07:27 PM
DAVID THOMSON	Officer	Dec 02 '25	Proposed Sale	5.43	147,780	802,445		Dec 02 04:24 PM
MICHAEL CASTAGNA	Director	Dec 02 '25	Proposed Sale	5.43	107,920	586,006		Dec 02 04:23 PM
Singh Sanjay R	EVP Technical Operations	Nov 14 '25	Sale	5.03	18,777	94,448	455,211	Nov 14 08:00 PM
SANJAY SINGH	Officer	Nov 14 '25	Proposed Sale	5.03	18,777	94,493		Nov 14 04:02 PM

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

CEO & DirectorDr. Michael E. Castagna Pharm.D.

Chief Financial OfficerMr. Christopher B. Prentiss M.B.A.

Ph.D.Dr. David B. Thomson J.D.

Chief People & Workplace OfficerDr. Stuart A. Tross Ph.D.

President of Endocrine Business UnitMr. Dominic Marasco R.Ph.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MNKD

Mannkind Corp

Upgrade your Finviz experience